NFKB1 and neoplasm: Recent work in tumor‐associated myeloid cells has shown that dual NFkB pathway manipulation is effective and improves tumor control.[8] This prior work used a 37 nm carbohydrate platform (CANDI) to deliver multiple small molecule immune modulators to tumor‐associated macrophages and a lesser degree to DCs.